Do analysts rate AGPU or POAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axe Compute 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend TCX or POAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tucows 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, VIVO or POAI?

Predictive Oncology has higher revenue and earnings than VivoPower PLC Ordinary Shares. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VivoPower PLC Ordinary Shares $60K 806.10 -$12.79M N/A N/A Predictive Oncology $1.66M 25.47 -$12.66M -$13.50 N/A

Do analysts recommend POAI or VVPR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vivopower International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, POAI or VVPR?

Predictive Oncology has higher revenue and earnings than Vivopower International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Predictive Oncology $1.66M 25.47 -$12.66M -$13.50 N/A Vivopower International $61K 790.64 -$12.79M N/A N/A

Do analysts recommend BIRD or POAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allbirds 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Predictive Oncology (POAI) Competitors

$12.49 -0.09 (-0.72%)

As of 09/22/2026

Compare

POAI vs. AGPU, TCX, VIVO, VVPR, and BIRD

Should you buy Predictive Oncology stock or one of its competitors? Predictive Oncology's main competitors and comparable companies include Axe Compute (AGPU), Tucows (TCX), VivoPower PLC Ordinary Shares (VIVO), Vivopower International (VVPR), and Allbirds (BIRD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "internet services & infrastructure" industry.

How does Predictive Oncology compare to Axe Compute?

Axe Compute (NASDAQ:AGPU) and Predictive Oncology (NASDAQ:POAI) are both small-cap technology companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

9.0% of Axe Compute shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 1.2% of Axe Compute shares are held by insiders. Comparatively, 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Axe Compute has a beta of 3.47, indicating that its stock price is 247% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

Predictive Oncology has a net margin of -5,065.23% compared to Axe Compute's net margin of -7,769.61%. Predictive Oncology's return on equity of -732.73% beat Axe Compute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axe Compute	-7,769.61%	-1,606.56%	-355.39%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

In the previous week, Axe Compute had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 1 mentions for Axe Compute and 0 mentions for Predictive Oncology. Axe Compute's average media sentiment score of 0.76 beat Predictive Oncology's score of 0.00 indicating that Axe Compute is being referred to more favorably in the media.

Company	Overall Sentiment
Axe Compute	Positive
Predictive Oncology	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axe Compute	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Predictive Oncology has lower revenue, but higher earnings than Axe Compute. Axe Compute is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axe Compute	$3.26M	40.82	-$233.10M	-$5.75	N/A
Predictive Oncology	$1.66M	25.47	-$12.66M	-$13.50	N/A

Summary

Axe Compute beats Predictive Oncology on 6 of the 11 factors compared between the two stocks.

How does Predictive Oncology compare to Tucows?

Tucows (NASDAQ:TCX) and Predictive Oncology (NASDAQ:POAI) are both small-cap technology companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Predictive Oncology has lower revenue, but higher earnings than Tucows. Tucows is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tucows	$390.30M	0.30	-$75.82M	-$7.53	N/A
Predictive Oncology	$1.66M	25.47	-$12.66M	-$13.50	N/A

In the previous week, Tucows' average media sentiment score of 0.00 equaled Predictive Oncology'saverage media sentiment score.

Company	Overall Sentiment
Tucows	Neutral
Predictive Oncology	Neutral

Tucows has a net margin of -21.20% compared to Predictive Oncology's net margin of -5,065.23%. Tucows' return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tucows	-21.20%	N/A	-9.48%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tucows	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

73.6% of Tucows shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 8.4% of Tucows shares are owned by company insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tucows has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

Summary

Tucows beats Predictive Oncology on 7 of the 11 factors compared between the two stocks.

How does Predictive Oncology compare to VivoPower PLC Ordinary Shares?

VivoPower PLC Ordinary Shares (NASDAQ:VIVO) and Predictive Oncology (NASDAQ:POAI) are both small-cap technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

15.8% of VivoPower PLC Ordinary Shares shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 2.3% of VivoPower PLC Ordinary Shares shares are held by company insiders. Comparatively, 1.2% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, VivoPower PLC Ordinary Shares' average media sentiment score of 0.00 equaled Predictive Oncology'saverage media sentiment score.

Company	Overall Sentiment
VivoPower PLC Ordinary Shares	Neutral
Predictive Oncology	Neutral

Predictive Oncology has higher revenue and earnings than VivoPower PLC Ordinary Shares.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoPower PLC Ordinary Shares	$60K	806.10	-$12.79M	N/A	N/A
Predictive Oncology	$1.66M	25.47	-$12.66M	-$13.50	N/A

VivoPower PLC Ordinary Shares has a beta of -0.65, indicating that its share price is 165% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

VivoPower PLC Ordinary Shares has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. VivoPower PLC Ordinary Shares' return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoPower PLC Ordinary Shares	N/A	N/A	N/A
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

VivoPower PLC Ordinary Shares presently has a consensus price target of $10.00, suggesting a potential upside of 159.07%. Given VivoPower PLC Ordinary Shares' stronger consensus rating and higher possible upside, research analysts clearly believe VivoPower PLC Ordinary Shares is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoPower PLC Ordinary Shares	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

VivoPower PLC Ordinary Shares beats Predictive Oncology on 9 of the 12 factors compared between the two stocks.

How does Predictive Oncology compare to Vivopower International?

Predictive Oncology (NASDAQ:POAI) and Vivopower International (NASDAQ:VVPR) are both small-cap technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vivopower International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Predictive Oncology has higher revenue and earnings than Vivopower International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	25.47	-$12.66M	-$13.50	N/A
Vivopower International	$61K	790.64	-$12.79M	N/A	N/A

In the previous week, Predictive Oncology's average media sentiment score of 0.00 equaled Vivopower International'saverage media sentiment score.

Company	Overall Sentiment
Predictive Oncology	Neutral
Vivopower International	Neutral

Predictive Oncology has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Vivopower International has a beta of -1.65, meaning that its stock price is 265% less volatile than the broader market.

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 15.8% of Vivopower International shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by insiders. Comparatively, 9.1% of Vivopower International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Vivopower International has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. Vivopower International's return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Vivopower International	N/A	N/A	N/A

Summary

Vivopower International beats Predictive Oncology on 6 of the 9 factors compared between the two stocks.

How does Predictive Oncology compare to Allbirds?

Allbirds (NASDAQ:BIRD) and Predictive Oncology (NASDAQ:POAI) are both small-cap technology companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Allbirds has a beta of 2.62, suggesting that its stock price is 162% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

Allbirds has a net margin of -72.82% compared to Predictive Oncology's net margin of -5,065.23%. Allbirds' return on equity of -231.86% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allbirds	-72.82%	-231.86%	-81.53%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

Predictive Oncology has lower revenue, but higher earnings than Allbirds. Predictive Oncology is trading at a lower price-to-earnings ratio than Allbirds, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allbirds	$152.47M	0.14	-$77.28M	-$8.99	N/A
Predictive Oncology	$1.66M	25.47	-$12.66M	-$13.50	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allbirds	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

44.1% of Allbirds shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 18.8% of Allbirds shares are owned by company insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Allbirds had 3 more articles in the media than Predictive Oncology. MarketBeat recorded 3 mentions for Allbirds and 0 mentions for Predictive Oncology. Allbirds' average media sentiment score of 0.53 beat Predictive Oncology's score of 0.00 indicating that Allbirds is being referred to more favorably in the media.

Company	Overall Sentiment
Allbirds	Positive
Predictive Oncology	Neutral

Summary

Allbirds beats Predictive Oncology on 12 of the 14 factors compared between the two stocks.

Get Predictive Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding POAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

POAI vs. The Competition

Export

Metric	Predictive Oncology	IT Services Industry	Technology Sector	NASDAQ Exchange
Market Cap	$42.39M	$11.19B	$31.38B	$13.29B
Dividend Yield	N/A	2.86%	2.75%	12.57%
P/E Ratio	-0.93	14.07	79.04	25.69
Price / Sales	25.47	62.92	590.12	78.88
Price / Cash	N/A	46.25	49.70	52.76
Price / Book	-27.15	8.38	8.01	6.32
Net Income	-$12.66M	$271.17M	$702.96M	$359.73M
7 Day Performance	13.65%	0.74%	1.40%	0.17%
1 Month Performance	22.33%	-1.17%	-1.08%	-3.27%
1 Year Performance	-29.44%	20.51%	178.52%	5.58%

Predictive Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
POAI Predictive Oncology	0.0561 of 5 stars	$12.49 -0.7%	N/A	-28.2%	$42.39M	$1.66M	N/A	30
AGPU Axe Compute	0.7941 of 5 stars	$11.80 +6.7%	N/A	N/A	$136.60M	$120K	N/A	14
TCX Tucows	0.0473 of 5 stars	$10.40 +0.9%	N/A	-44.8%	$118.13M	$390.30M	N/A	759	Positive News Analyst Upgrade
VIVO VivoPower PLC Ordinary Shares	1.2979 of 5 stars	$3.76 flat	$10.00 +166.0%	N/A	$47.11M	$60K	N/A	41
VVPR Vivopower International	0.0081 of 5 stars	$3.76 -3.6%	N/A	-20.1%	$47.10M	$61K	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:POAI) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Predictive Oncology (POAI) Competitors

POAI vs. AGPU, TCX, VIVO, VVPR, and BIRD

How does Predictive Oncology compare to Axe Compute?

Summary

How does Predictive Oncology compare to Tucows?

Summary

How does Predictive Oncology compare to VivoPower PLC Ordinary Shares?

Summary

How does Predictive Oncology compare to Vivopower International?

Summary

How does Predictive Oncology compare to Allbirds?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POAI vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Predictive Oncology (POAI) Competitors

POAI vs. AGPU, TCX, VIVO, VVPR, and BIRD

How does Predictive Oncology compare to Axe Compute?

Do insiders and institutionals hold more shares of AGPU or POAI?

Which has more risk & volatility, AGPU or POAI?

Is AGPU or POAI more profitable?

Does the media favor AGPU or POAI?

Do analysts rate AGPU or POAI?

Which has higher valuation & earnings, AGPU or POAI?

Summary

How does Predictive Oncology compare to Tucows?

Which has preferable earnings and valuation, TCX or POAI?

Does the media favor TCX or POAI?

Is TCX or POAI more profitable?

Do analysts recommend TCX or POAI?

Do institutionals & insiders have more ownership in TCX or POAI?

Which has more volatility & risk, TCX or POAI?

Summary

How does Predictive Oncology compare to VivoPower PLC Ordinary Shares?

Do institutionals & insiders hold more shares of VIVO or POAI?

Does the media favor VIVO or POAI?

Which has preferable earnings and valuation, VIVO or POAI?

Which has more volatility and risk, VIVO or POAI?

Is VIVO or POAI more profitable?

Do analysts prefer VIVO or POAI?

Summary

How does Predictive Oncology compare to Vivopower International?

Do analysts recommend POAI or VVPR?

Which has higher valuation & earnings, POAI or VVPR?

Does the media refer more to POAI or VVPR?

Which has more risk & volatility, POAI or VVPR?

Do institutionals & insiders have more ownership in POAI or VVPR?

Is POAI or VVPR more profitable?

Summary

How does Predictive Oncology compare to Allbirds?

Which has more risk and volatility, BIRD or POAI?

Is BIRD or POAI more profitable?

Which has higher valuation & earnings, BIRD or POAI?

Do analysts recommend BIRD or POAI?

Do insiders & institutionals believe in BIRD or POAI?

Does the media favor BIRD or POAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POAI vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools